These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3102636)

  • 1. Ofloxacin therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa.
    Norden CW; Niederriter K
    J Infect Dis; 1987 Apr; 155(4):823-5. PubMed ID: 3102636
    [No Abstract]   [Full Text] [Related]  

  • 2. Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa.
    Norden CW; Shinners E
    J Infect Dis; 1985 Feb; 151(2):291-4. PubMed ID: 3155780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of tobramycin and azlocillin alone and in combination against experimental osteomyelitis caused by Pseudomonas aeruginosa.
    Norden CW; Shaffer MA
    Antimicrob Agents Chemother; 1982 Jan; 21(1):62-5. PubMed ID: 6805423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudomonas Aeruginosa Osteomyelitis of the Pubic Bone: A Case Report.
    Siyahkali SJM; SeyedAlinaghi S; Samaei M; Taj L
    Infect Disord Drug Targets; 2018; 18(2):177-179. PubMed ID: 28707596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy.
    Gentile I; Buonomo AR; Maraolo AE; Scotto R; De Zottis F; Di Renzo G; Borgia G
    J Antimicrob Chemother; 2017 Sep; 72(9):2678-2679. PubMed ID: 28575437
    [No Abstract]   [Full Text] [Related]  

  • 6. Emergence of ofloxacin-resistant Citrobacter freundii and Pseudomonas maltophilia after ofloxacin therapy.
    Cheng AF; Li MK; Ling TK; French GL
    J Antimicrob Chemother; 1987 Aug; 20(2):283-5. PubMed ID: 3478330
    [No Abstract]   [Full Text] [Related]  

  • 7. Ofloxacin-delivery system of a polyanhydride and polylactide blend used in the treatment of bone infection.
    Chen L; Wang H; Wang J; Chen M; Shang L
    J Biomed Mater Res B Appl Biomater; 2007 Nov; 83(2):589-95. PubMed ID: 17410574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clarithromycin destroys biofilms and enhances bactericidal agents in the treatment of Pseudomonas aeruginosa osteomyelitis.
    Kandemir O; Oztuna V; Milcan A; Bayramoğlu A; Celik HH; Bayarslan C; Kaya A
    Clin Orthop Relat Res; 2005 Jan; (430):171-5. PubMed ID: 15662320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcaneal osteomyelitis caused by Pseudomonas aeruginosa without foot injury.
    Hoshina Y; Nakao H; Yoshida M; Kubota M; Ishiguro A
    Pediatr Int; 2021 May; 63(5):601-602. PubMed ID: 33818855
    [No Abstract]   [Full Text] [Related]  

  • 10. Ofloxacin: therapeutic activity in experimental infections.
    Guerra L; Erani E; Xerri L
    Chemioterapia; 1986 Dec; 5(6):375-8. PubMed ID: 3467874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of ofloxacin treatment of experimental urinary tract infections].
    Ritzerfeld W
    Infection; 1986; 14 Suppl 1():S45-6. PubMed ID: 3514471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes.
    Dietl B; Sánchez I; Arcenillas P; Cuchi E; Gómez L; González de Molina FJ; Boix-Palop L; Nicolás J; Calbo E
    Int J Antimicrob Agents; 2018 Mar; 51(3):498-502. PubMed ID: 29158144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of Pseudomonas aeruginosa osteomyelitis with antibiotic monotherapy of limited duration.
    Laghmouche N; Compain F; Jannot AS; Guigui P; Mainardi JL; Lonjon G; Bouyer B; Fernandez-Gerlinger MP
    J Infect; 2017 Sep; 75(3):198-206. PubMed ID: 28668598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bone infections: treatment by ofloxacin. Apropos of 10 cases].
    Bernard E; Etesse H; Garraffo R; Giaume F; Dellamonica P
    Pathol Biol (Paris); 1987 May; 35(5):644-7. PubMed ID: 3302877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel in vitro pharmacodynamic model simulating ofloxacin pharmacokinetics in the treatment of Pseudomonas aeruginosa biofilm-associated infections.
    Noreddin AM; Elkhatib WF
    J Infect Public Health; 2009; 2(3):120-8. PubMed ID: 20701871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mandibular osteomyelitis due to Pseudomonas aeruginosa. Case report.
    Pappalardo S; Tanteri L; Brutto D; Marescalco M; Carlino V; Consolo G; Mauro M; Cappello V
    Minerva Stomatol; 2008 Jun; 57(6):323-9. PubMed ID: 18617880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future perspectives for levofloxacin in severe Pseudomonas aeruginosa infections.
    Marchetti F; Viale P
    J Chemother; 2003 Aug; 15(4):315-22. PubMed ID: 12962358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Osteomyelitis by Pseudomonas aeruginosa in a submariner].
    García J; Monfort J; Blanch J; Benito P
    Med Clin (Barc); 2005 May; 124(20):795-6. PubMed ID: 15927108
    [No Abstract]   [Full Text] [Related]  

  • 19. Ofloxacin in oral chemotherapy of acute and chronic otitis media.
    Lenarz T
    Infection; 1986; 14 Suppl 4():S324-6. PubMed ID: 3469167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aztreonam therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa.
    Norden CW; Budinsky A
    J Infect Dis; 1988 Sep; 158(3):660-1. PubMed ID: 3411154
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.